Ancestry matters: Building inclusivity into preclinical study design
- PMID: 33989545
- DOI: 10.1016/j.cell.2021.03.041
Ancestry matters: Building inclusivity into preclinical study design
Abstract
Human cell lines (CLs) are key assets for biomedicine but lack ancestral diversity. Here, we explore why genetic diversity among cell-based models is essential for making preclinical research more equitable and widely translatable. We lay out practical actions that can be taken to improve inclusivity in study design.
Keywords: GWAS; HeLa; ancestry; cell lines; diversity; drug discovery; pharmacogenomics; precision medicine.
Copyright © 2021 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests S.Z. is the founder of FIND Genomics, a company that aims to improve reproducible cell-based science. FIND Genomics is the creator of FIND Cell, a cell-line tracking software (https://findgen.bio/). A.C.D. receives payments as a consultant for FIND Genomics.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources